Please note: The license is valid for 12 months from the date the report is sent.
The Ebola Report - new study showing you trends and R&D progress
What opportunities are there in a market for Ebola diagnostics, prevention, and treatment? What are the commercial prospects for this market and related technologies? Visiongain’s new report shows market potential for products and other trends, discussing data, opportunities and prospects.
Our new 115 page report provides 40 tables, charts, and graphs. Discover the R&D prospects of products in the pipeline and their future market potential. Our new study lets you assess the leading candidates in the race for entry into the market for Ebola diagnostics, vaccines, and treatments. You will see interviews, trends, and opportunities that may arise.Future outlook and other analyses show you commercial prospects
Our new study provides you with original analyses, with business outlooks and developments. Discover qualitative analyses, product profiles and commercial developments. Read the full transcripts of two exclusive expert opinion interviews from industry specialists informing your understanding and allowing you to assess prospects for investments and sales:
- Prof. Sunetra Gupta, Professor of Theoretical Epidemiology, University of Oxford
- Dr Derek Gatherer, Division of Biomedical and Life Sciences, Lancaster UniversityYou find prospects for the R&D pipeline of key submarkets
What is happening in the R&D pipeline for Ebola diagnostics, drugs and vaccines? You see developmental trends, gaining insight into the current products in development. In addition to analyses of currently used Ebola pharma/Medtech products, you see analyses for the pipeline of these three product categories:
- Ebola diagnostics
- Ebola treatments
- Ebola vaccines
Drugs that can significantly reduce the high mortality rate associated with infections with the Ebola virus whilst reducing the many grievous symptoms will achieve success. Vaccines aimed at protecting front-line healthcare workers treating patients infected with the Ebola virus will prove successful and financially viable to developers and manufacturers
Our investigation shows business research and analyses with individual product evaluations and discussions. You find the dynamics of the industry and assess its potential growth, seeing agents likely to achieve the most success.See insightful analysis for products
What are the characteristics of the most promising drugs and vaccines being developed or tested to treat or prevent Ebola? How will promising products currently in the pipeline perform once they are launched? Our study profiles promising Ebola drugs including these:
- TKM-EbolaYou will see what is happening, understanding trends, challenges and opportunities. Discover features and profiles for Ebola vaccines currently under development. These include:
- GSK’s ChAd vaccine
- New Link Genetic Corp’s rVSV vaccine
- Johnson & Johnson/ Bavarian Nordic AdVac/ MVA-BN Technology-based vaccineWhat are the prospects for the various regions and countries?
Which countries are most at risk? Which countries are best prepared to tackle potential cases of Ebola? Regulatory approvals and the trends being observed for some products getting fast tracked will play a crucial role in shaping the future of the market for Ebola drugs and vaccines. Our analyses show a rapid uptake for products targeting the Ebola virus and Ebola virus disease on the back of the devastation caused by the Ebola virus disease outbreak in West Africa in 2014. In particular, the countries in North America and Europe will look to stock up on Ebola drugs and vaccines to counter the risk of Ebola virus disease spreading into the region. Furthermore, the potential threat of the Ebola virus be
Get Industry Insights. Simply.
- Latest reports & slideshows with insights from top research analysts
- 60 Million searchable statistics with tables, figures & datasets
- More than 25,000 trusted sources